Esper Boel

Biography

 35 years of experience in international biopharmaceutical R&D from working with groups in Seattle, Beijing, Marseille, Aarhus and Copenhagen, including 22 years as a leader of R&D units at Novo Nordisk. During the last 15 years the focus has been on immunotherapy-based treatment of inflammatory conditions and cancer. He has served as member of the executive team, as BoD member and as senior advisor for high-profile antibody- and immunology-based companies like Symphogen A/S, Xencor Inc., Bavarian Nordic A/S, Innate Pharma SA, ResoTher Pharma Aps, MonTa Bioscience and ALK-Abelló A/S and he has (co)authored 75 original research articles and reviews within several scientific and biomedical disciplines.

Research Interest

  immunotherapy-based treatment of inflammatory conditions and cancer